236 related articles for article (PubMed ID: 19997101)
1. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.
Mallett S; Timmer A; Sauerbrei W; Altman DG
Br J Cancer; 2010 Jan; 102(1):173-80. PubMed ID: 19997101
[TBL] [Abstract][Full Text] [Related]
2. Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles.
Sekula P; Mallett S; Altman DG; Sauerbrei W
PLoS One; 2017; 12(6):e0178531. PubMed ID: 28614415
[TBL] [Abstract][Full Text] [Related]
3. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.
Altman DG; McShane LM; Sauerbrei W; Taube SE
PLoS Med; 2012; 9(5):e1001216. PubMed ID: 22675273
[TBL] [Abstract][Full Text] [Related]
4. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.
Sauerbrei W; Taube SE; McShane LM; Cavenagh MM; Altman DG
J Natl Cancer Inst; 2018 Aug; 110(8):803-811. PubMed ID: 29873743
[TBL] [Abstract][Full Text] [Related]
5. Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines.
Jankova L; Dent OF; Molloy MP; Chan C; Chapuis PH; Howell VM; Clarke SJ
Proteomics Clin Appl; 2015 Dec; 9(11-12):1078-86. PubMed ID: 25755195
[TBL] [Abstract][Full Text] [Related]
6. Structured reporting to improve transparency of analyses in prognostic marker studies.
Sauerbrei W; Haeussler T; Balmford J; Huebner M
BMC Med; 2022 May; 20(1):184. PubMed ID: 35546237
[TBL] [Abstract][Full Text] [Related]
7. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.
Altman DG; McShane LM; Sauerbrei W; Taube SE
BMC Med; 2012 May; 10():51. PubMed ID: 22642691
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic (STARD) and prognostic (REMARK) studies].
Altman DG; Bossuyt PM; ;
Med Clin (Barc); 2005 Dec; 125 Suppl 1():49-55. PubMed ID: 16464428
[TBL] [Abstract][Full Text] [Related]
9. A Survey of the Prevalence and Impact of Reporting Guideline Endorsement in Pathology Journals.
Caron JE; March JK; Cohen MB; Schmidt RL
Am J Clin Pathol; 2017 Oct; 148(4):314-322. PubMed ID: 28967948
[TBL] [Abstract][Full Text] [Related]
10. Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.
Draht MXG; Goudkade D; Koch A; Grabsch HI; Weijenberg MP; van Engeland M; Melotte V; Smits KM
Clin Epigenetics; 2018; 10():35. PubMed ID: 29564023
[TBL] [Abstract][Full Text] [Related]
11. REporting recommendations for tumour MARKer prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
Br J Cancer; 2005 Aug; 93(4):387-91. PubMed ID: 16106245
[TBL] [Abstract][Full Text] [Related]
12. Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies.
Fung AE; Palanki R; Bakri SJ; Depperschmidt E; Gibson A
Ophthalmology; 2009 Feb; 116(2):286-96. PubMed ID: 19091408
[TBL] [Abstract][Full Text] [Related]
13. REporting recommendations for tumour MARKer prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
Eur J Cancer; 2005 Aug; 41(12):1690-6. PubMed ID: 16043346
[TBL] [Abstract][Full Text] [Related]
14. Publication of tumor marker research results: the necessity for complete and transparent reporting.
McShane LM; Hayes DF
J Clin Oncol; 2012 Dec; 30(34):4223-32. PubMed ID: 23071235
[TBL] [Abstract][Full Text] [Related]
15. Reporting and Methodology of Multivariable Analyses in Prognostic Observational Studies Published in 4 Anesthesiology Journals: A Methodological Descriptive Review.
Guglielminotti J; Dechartres A; Mentré F; Montravers P; Longrois D; Laouénan C
Anesth Analg; 2015 Oct; 121(4):1011-1029. PubMed ID: 25390276
[TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
17. Quality of reporting of diagnostic accuracy studies.
Smidt N; Rutjes AW; van der Windt DA; Ostelo RW; Reitsma JB; Bossuyt PM; Bouter LM; de Vet HC
Radiology; 2005 May; 235(2):347-53. PubMed ID: 15770041
[TBL] [Abstract][Full Text] [Related]
18. REMARK guidelines for tumour biomarker study reporting: a remarkable history.
Hayes DF; Sauerbrei W; McShane LM
Br J Cancer; 2023 Feb; 128(3):443-445. PubMed ID: 36476656
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts.
Iafolla MAJ; Picardo S; Aung K; Hansen AR
PLoS One; 2019; 14(10):e0222359. PubMed ID: 31639128
[TBL] [Abstract][Full Text] [Related]
20. REporting recommendations for tumor MARKer prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
Breast Cancer Res Treat; 2006 Nov; 100(2):229-35. PubMed ID: 16932852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
